Hexyon

Hexyon is a combination DTaP‑IPV‑Hib vaccine that includes diphtheria toxoid, tetanus toxoid, pertussis antigens, inactivated poliovirus, and Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate). It is provided as a sterile injectable solution for intramuscular administration. Hexyon is marketed in the European Union and is prescribed by healthcare professionals to protect against diphtheria, tetanus, pertussis, poliomyelitis, and Hib disease. It follows recommended pediatric schedules and adult boosters.

Hexyon is used to actively immunise individuals against five serious infectious diseases as part of routine childhood vaccination programs.

- Diphtheria, providing protection by stimulating antibodies against diphtheria toxin. - Tetanus, inducing immunity to tetanus neurotoxin. - Pertussis (whooping cough), generating antibodies to pertussis antigens. - Poliomyelitis, preventing infection with inactivated poliovirus types. - Haemophilus influenzae type b disease, reducing risk of invasive Hib infections.

Following vaccination with Hexyon, some recipients experience mild to moderate reactions, while rare serious events may occur.

Common: - Pain, redness or swelling at the injection site. - Low‑grade fever lasting 1–2 days. - Irritability or fussiness in infants. - Mild headache or fatigue.

Serious: - Anaphylactic or severe allergic reaction. - Seizure (rarely reported). - High fever with rash. - Persistent crying or inconsolable distress.

Healthcare providers should assess individual health status before administering Hexyon and follow recommended guidelines.

- Contraindicated in persons with a known severe allergy to any vaccine component. - Postpone vaccination in individuals with moderate or severe acute illness. - Use caution in immunocompromised patients, as response may be reduced. - Pregnancy status should be evaluated; safety data are limited. - Monitor for signs of anaphylaxis for at least 15 minutes after injection. - Do not co‑administer with live vaccines in the same visit.

Hexyon may interact with other medical products; certain combinations should be avoided or used with caution.

Avoid: - Simultaneous administration with live attenuated vaccines (e.g., measles‑mumps‑rubella) in the same injection site. - Concurrent use of immunoglobulin or blood products that could interfere with vaccine efficacy.

Use with caution: - Administration with other inactivated vaccines may be spaced according to schedule. - Patients receiving immunosuppressive therapy may have diminished antibody response. - Antipyretics may mask fever, but are generally acceptable for symptom relief.